Eloxx Pharmaceuticals Inc (ELOX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$
Buy
$
$ (+%)
Prices updated at 13 Dec 2025, 23:37
| Prices minimum 15 mins delay
Prices in USD
Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Tomer Kariv
CEO
Mr. Sumit Aggarwal
Most recent earnings
31 Dec 2022
Fiscal year end
31 Dec 2022
Employees
18
Head office
P.O. Box 274
Arlington
United States
02476
Key personnel
Owner name | Salary |
|---|---|
Mr. Steven D. Rubin Independent Director | 0.06m |
Mr. Tomer Kariv Chairman of the Board | 0.05m |
Mr. Daniel E. Geffken, M.B.A. Interim Chief Financial Officer and Principal Accounting Officer | - |
Mr. Sumit Aggarwal Director, President and Chief Executive Officer | 0.58m |
Dr. Alan Walts Independent Director | 0.06m |
Ms. Lindsay Androski Independent Director | 0.03m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Northern Trust Investments Inc | 101 |
| NT Quality SCC US Fund - L | 101 |
| Northern Trust Asset Management | - |
| BlackRock Asset Management Canada Ltd | - |
| BlackRock Fund Advisors | - |
Director dealings
Date | Action |
|---|---|
| 16 Oct 2024 | - |
| 16 Oct 2024 | - |
| 16 Oct 2024 | - |
| 16 Oct 2024 | - |
| 24 Jan 2024 | - |
| 24 Jan 2024 | - |
| 24 Jan 2024 | - |
| 24 Jan 2024 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
| 24 Jan 2025 | - |
Please note that past performance is not a reliable indicator of future returns.